Open AccessThe effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps.
Author(s) -
De Schryver E,
Lara Derycke,
Lien Calus,
Gabriële Holtappels,
Peter Hellings,
Van Zele T,
Claus Bachert,
Philippe Gevaert
Publication year - 2017
Publication title -
pubmed
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.275
H-Index - 57
eISSN - 2589-0085
pISSN - 0300-0729
DOI - 10.4193/rhino16.314
Subject(s) - medicine , periostin , mepolizumab , nasal polyps , methylprednisolone , gastroenterology , sinusitis , omalizumab , eosinophilic , asthma , immunology , pathology , eosinophil , immunoglobulin e , antibody , extracellular matrix , biology , microbiology and biotechnology
Periostin is a recently discovered biomarker for eosinophilic inflammation. Chronic rhinosinusitis with nasal polyps is a T-helper 2-skewed chronic inflammatory airway disease. Medical treatments aim to relieve symptoms and maintain clinical control by interfering with the inflammatory cascade. The effect on nasal and serum periostin levels is however yet unknown. We aimed to evaluate the effect of omalizumab, mepolizumab, methylprednisolone and doxycycline on nasal and systemic periostin expression.